Introduction {#Sec1}
============

Breast cancer (BC) is one of the most common health threatening problems among women in the world, leading to death of those patients with BC^[@CR1]^. It has been reported in 2019 that the incidence and mortality of breast cancer worldwide are 24.2% and 15.0%, respectively, deserving more attention from healthcare systems and policy-makers^[@CR1]^. To clinically classify the status of breast cancer, the American Joint Committee on Cancer (AJCC) has announced eight editions on the Tumor-Node-Metastasis (TNM)-based staging of breast cancer, specifically for treatment and prognosis^[@CR2],[@CR3]^. Since more than 50% of the affected patients were died, increasing the survival rate of these patients is highly important by determining the stage of the disease. The earlier the identification of the stage, the more superior the survival rate. To increase the therapeutic efficiency and consider the molecular portrait differences in BC along with their different clinical outcomes^[@CR4]^, breast cancer can be classified into six main subtypes, including normal-like, luminal A, luminal B, HER2-positive, basal-like, and claudin-low^[@CR5]^; the classification has also been confirmed by the Cancer Genome Atlas (TCGA) program^[@CR6]^.

It has been frequently reported that the human epidermal growth factor receptor (HER) family (i.e., HER-1, HER-2, HER-3, and HER-4) plays a pivotal role in various cancers^[@CR7]^. Among them, HER-2 (known as HER-2/neu gene), as an oncogene with 1,255 amino acids and 185kD transmembrane glycoprotein with tyrosine kinase activity, is located at chromosome 17^[@CR7],[@CR8]^. Moreover, HER-2/neu gene makes breast cancer classified as HER2-positive and HER2-negative^[@CR9]^. In 15--30% of patients with invasive breast carcinomas, an overexpression or amplification of HER2 has been identified^[@CR7],[@CR10]^.

It is worth mentioning that is not effective for HER2-negative. Although, endocrine therapy is the target of chemotherapy, there are no successful reports for survival rates of these types of patients in the literature^[@CR11]^. Moreover, several traditional diagnostic approaches such as mammography, magnetic resonance imaging (MRI), ultrasound, computerized tomography (CT), positron emission tomography (PET), and biopsy have been studied in breast cancer diagnosis^[@CR12]^.

Nowadays, molecular biomarkers have been proposed to provide more efficiency in the prognosis and diagnosis of cancers in deficiency of traditional cancer tests. Additionally, the biomarkers are now regularly utilized to better understand the development of the tumors^[@CR13]^. Hence, owing to the large number of stored microarray gene expression profiles by several genomics laboratories in the most publicly available database websites such as National Center for Biotechnology Information (NCBI), their analyses by various bioinformatics and systems biology analyses are essential^[@CR4]^. Finally, these biomarkers will be helpful in personalizing the treatments for each patient with their special stage of the disease^[@CR4]^. Considering the HER2-targeted therapy, there are still no predictive biomarkers validated for the prognosis and diagnosis of the stages of breast cancer^[@CR14],[@CR15]^.

Consequently, the aim of the current study is to identify the potential biomarkers in breast cancer at stages I, II, III, IV as well as in the integrated group simultaneously regarded as one. To reach this aim, three microarray gene expression profiling datasets have been included to identify the differentially expressed genes (DEGs). By prioritizing those DEGs, their cellular and molecular functions will be further analyzed. Then, the involved GO (Gene Ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) signaling pathways will be studied. Moreover, the protein--protein interaction network for all stages are developed based on the STRING database, and the significant hub genes are identified by clustering algorithm from which the gene biomarkers will later be determined based on their higher connectivity degrees. Finally, the Kaplan--Meier analysis tool was used to assess recurrence-free survival rates of the identified gene biomarkers.

Materials and methods {#Sec2}
=====================

Figure [1](#Fig1){ref-type="fig"} presents the summarization of the flowchart diagram of the approach to satisfy the research question.Figure 1Flowchart of the current research approach step by step to achieve the final validated gene biomarkers in terms of recurrence free survival in HER2-negative breast cancer.

Data sources {#Sec3}
------------

All the datasets used in this study were retrieved from the NCBI GEO database (i.e., <https://www.ncbi.nlm.nih.gov/geo/>). The platform and file type of the breast cancer microarray datasets were GPL96 \[HG-U133A\] Affymetrix Human Genome U133A Array and CEL files, respectively. To cover the aim of this study, GSE124647, GSE129551, and GSE124646 were used as train set including 140 biopsy samples from metastatic patients with stage IV breast cancer, 147 samples from patients with stages I, II, III, and IV breast cancer, and 10 normal samples (0 percent cancer) out of 100 samples, respectively. Moreover, GSE15852 (i.e., includes 43 normal, 8 grade 1 \~ stage I, 23 grade 2 \~ stage II, and 12 grade 3 \~ stage III samples) was used as a test set for external validation.

Data preprocessing and identification of differentially expressed genes (DEGs) {#Sec4}
------------------------------------------------------------------------------

The BRB-ArrayTools (v4.6.0, stable version), an excel graphical user interface (GUI) for communicating with R (v 3.5.1) programming environment developed by Dr. Richard Simon and the BRB-ArrayTools Development Team, was used for all stages of preprocessing (i.e., data import, data filtering, and normalization), gene annotation using "hthgu133a.db" R annotation package^[@CR16]^ and identification of DEGs. During the data import phase, Microarray Suite version 5.0 (MAS 5.0) algorithm was utilized, and then spot filtering, quantile normalization, and gene filtering (gene exclusion criteria of fold change ≤ 2 with expression data values less than %20) were carried out. Next, class comparison between groups of arrays in terms of their label classification was performed to identify the differentially expressed genes (DEGs) by enabling the two options, including univariate permutation tests and restricting gene list based on the fold change threshold with their default values (i.e., 10,000 and 2, respectively). All of the identified DEGs were stored for the next stage (i.e., prioritization of DEGs) as test group. Furthermore, the volcano plot and box plot of the imported data were demonstrated for each stage versus the normal samples.

Prioritization for DEGs {#Sec5}
-----------------------

To prioritize identified DEGs from the previous section using the evidence of the literature, GeneCards^[@CR17]^ and ToPPGene^[@CR18]^ websites were used, respectively. The GeneCards database site (i.e., <https://genecards.org>) was used to extract the literature evidence on reported genes (denoted by the train group) for a specific disease by using approximately 150 web sources and the keywords. For this purpose, the used keywords included \< "breast cancer" + "stage I" \> , \< "breast cancer" + "stage II" \> , \< "breast cancer" + "stage III" \> , \< "breast cancer" + "stage IV" \> , as well as inclusion of the results of all four stages. Then, the ToPPGene website (i.e., <https://toppgene.cchmc.org>), which used the functional annotation and protein interactions to prioritize the imported gene list, was used to order the test group of genes based on the train group to determine the most significant DEGs in all stages of breast cancer with the p-value less than 0.05. Moreover, the ToPPGene website uses the similarity scores of the train group based on fuzzy and Pearson correlation measurement values to score and rank the test group.

Gene ontology, pathway and functional enrichment analyses of prioritized DEGs {#Sec6}
-----------------------------------------------------------------------------

To determine the biological and molecular functional processes of the prioritized gene list as well as their significant enriched pathways, the online tool provided in the DAVID v. 6.8 (Database for Annotation, Visualization, and Integrated Discovery) website (i.e., <https://david.abcc.ncifcrf.gov/summary.jsp>)^[@CR19],[@CR20]^ was applied. This website took the advantages of the gene ontology (GO) annotation analysis and the Kyoto Encyclopedia of Genes and Genomes (KEGG) to cover the required properties. Moreover, the results with the p-value ≤ 0.05 were considered significant.

Protein--protein interaction (PPI) network construction {#Sec7}
-------------------------------------------------------

The protein--protein interaction network among prioritized DEGs was constructed by the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING database ver. 11 plugin^[@CR21]^ for Cytoscape v.3.7.1^[@CR22]^). The current STRING database (since January 19, 2019) contains 24,584,628 proteins from 5,090 organisms with 3,123,056,667 interactions. Moreover, the STRING database is experimentally dependent on BIND, DIP, GRID, HPRD, IntAct, MINT, and PID, and the cumulative information is extracted from curated websites Biocarta, BioCyc, GO, KEGG, and Reactome^[@CR21]^. During the gene list import using the Cytoscape software, the confidence score cutoff value was set as 0.4 for PPI network construction and visualization. In the PPI network, the involved proteins are denoted by nodes, and their corresponding protein--protein interactions are presented as edges. To further investigate the PPI network of each of the breast cancer stages, the module (hub gene) analysis was performed using ClusterOne v.1.0 cytoscape plugin^[@CR23]^ with its default values. Then, the significant modules with the p-value ≤ 0.05 were retrieved for biomarker identification. A protein with the highest connectivity degree in each candidate module will be considered a biomarker.

Validation of gene biomarkers {#Sec8}
-----------------------------

To validate the identified gene biomarkers for each stage, three validation approaches were considered. These include (i) the Kaplan--Meier (KM) plotter tool, (ii) classification model development and validation, and (iii) literature search for the identified gene biomarkers.

### Kaplan--Meier plotter tool {#Sec9}

To further validate the prognostic value of the gene biomarkers obtained from the hub genes of five groups, the free online Kaplan--Meier (KM) plotter tool was used^[@CR24],[@CR25]^. Using the KM plotter tool, a meta-analysis based approach on thirty-five separate datasets was presented to assess the gene biomarkers in terms of various survival rates such as relapse free survival (RFS) and overall survival (OS). However, it has been reported that there is no significant difference between recurrence or relapse or disease free survival and overall survival rates^[@CR26],[@CR27]^. To this end, the relapse free survival (RFS) (n = 3,955) was used by restricting the analysis to only HER2 (ERBB2) considering the HER2 nature of the three abovementioned datasets. Moreover, to generate high-resolution images, an option, namely "Generate high resolution TIFF file" was enabled before drawing the Kaplan--Meier plot and then, their *p-*values were recorded for target biomarkers. Additionally, by analyzing the RFS rate, the clinical outcomes of a disease would be measured if the time to death of the patient would be observed rather than validating the prognostic value of the gene biomarkers at particular stages of a disease.

### Classification model development and validation {#Sec10}

To validate the prognostic value of the identified biomarkers for a specific disease, a non-linear classification model was developed. For this purpose, nine classification models in Orange 3.22.0, including support vector machine, k-nearest neighbors, stochastic gradient descent, random forest, artificial neural network, Naïve Bayes, logistic regression, CN2 rule inducer, and adaboost were considered^[@CR28]^. Furthermore, cross-validated accuracy (CA), precision (positive predictive value), recall (sensitivity), F1 score (a harmonic mean of sensitivity), and AUC (area under curve) were assessed using validation criteria such as *k*-fold cross-validation (*k* = *5, 10),* LOOV (leave-one-out validation) as well as testing the model on train and test sets. Overall, the developed models would be validated both internally and externally.$$\documentclass[12pt]{minimal}
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### Literature screening for potential genes {#Sec11}

Another way of validating the identified genes was carried out based on the frequent appearance of the reported genes through experimental wet-labs of the literature investigations for the disease.

Results {#Sec12}
=======

Data preprocessing {#Sec13}
------------------

The numbers of genes remained after applying the filtering criteria at stages I (normal:10, stage I:20), II (normal:10, stage II:80), III (normal:10, stage III:15), IV (normal:10, stage IV:141), and in the integrated group (normal:10, all samples at stage I, II, III, and IV:256) were 1,873, 2,034, 2,016, 2,279, and 2,471, respectively. Among the filtered genes, 832 (341 downregulated genes and 491 upregulated genes), 836 (392 downregulated genes and 444 upregulated genes), 980 (444 downregulated genes and 536 upregulated genes), 731 (455 downregulated genes and 276 upregulated genes), and 735 (464 downregulated genes and 271 upregulated genes) DEGs were identified using the two-sample t-test for the order of the abovementioned stages.

Prioritization of DEGs {#Sec14}
----------------------

After searching the GeneCards database for the specified breast cancer terms, 2,264, 1,611, 1,856, 855, and 6,586 DEGs for stages I, II, III, IV, and the integrated group were extracted and exported as a .csv file and were set as training datasets for five groups, separately. Moreover, the identified DEGs for five groups from BRB-ArrayTools were set as test datasets. Then, the ToppGene database ranked the input test datasets based on training datasets in five groups separately for each stage. Considering the threshold of the p-value \< 0.05, the numbers of the selected DEGs for the above order of stages were 287, 339, 365, 347, and 224 that could play an important role in five specified stages of breast cancer. Among those DEGs identified for stage I, 131 genes were downregulated and 156 genes were upregulated. The values of downregulated and upregulated genes for stages II, III, IV and all stage were 174 and 165, 176 and 189, 218 and 129 as well as 134 and 90, respectively. Table [1](#Tab1){ref-type="table"} presents the list of the top 10 upregulated and downregulated genes ranked for all stages considering their low *p*-values.Table 1Top 10 ranked genes resulted from ToppGene website based on significant p-values.RankGene symbolGene nameExpressionOverall *p-*value**Stage I**1CDK5cyclin dependent kinase 5Downregulated7.44E−042PSEN2presenilin 2Downregulated9.04E−043IKBKBinhibitor of nuclear factor kappa B kinase subunit betaDownregulated9.11E−044PRNPprion proteinUpregulated0.0012225465ITGB4integrin subunit beta 4Upregulated0.0013262326DDX58DExD/H-box helicase 58Downregulated0.0013379167BIN1bridging integrator 1Upregulated0.0014045778SPRY2sprouty RTK signaling antagonist 2Upregulated0.0015848779PYCARDPYD and CARD domain containingDownregulated0.00161506510EDNRBendothelin receptor type BUpregulated0.002032487**Stage II**1CDK5cyclin dependent kinase 5Downregulated6.37E−042FN1fibronectin 1Downregulated6.57E−043PRKCDprotein kinase C deltaDownregulated7.17E−044ADRB2adrenoceptor beta 2Upregulated8.56E−045PRNPprion proteinUpregulated9.66E−046ITGB4integrin subunit beta 4Upregulated0.0010214947DDX58DExD/H-box helicase 58Downregulated0.0011779868NTRK2neurotrophic receptor tyrosine kinase 2Upregulated0.0013275669PYCARDPYD and CARD domain containingDownregulated0.00132836210TFRCtransferrin receptorDownregulated0.001379303**Stage III**1PRKCDprotein kinase C deltaDownregulated6.06E−042CDK5cyclin dependent kinase 5Downregulated6.15E−043PSEN2presenilin 2Downregulated6.84E−044IKBKBinhibitor of nuclear factor kappa B kinase subunit betaDownregulated8.94E−045ITGB4integrin subunit beta 4Upregulated0.0010866986FOSFos proto-oncogene, AP-1 transcription factor subunitUpregulated0.0010976747BMPR1Abone morphogenetic protein receptor type 1AUpregulated0.0011430678ATP1A2ATPase Na + /K + transporting subunit alpha 2Upregulated0.0012192889GSNgelsolinUpregulated0.00129546610TCF7L2transcription factor 7 like 2Upregulated0.001296722**Stage IV**1APPamyloid beta precursor proteinDownregulated3.64E−042CAV1caveolin 1Downregulated3.81E−043GNASGNAS complex locusUpregulated3.87E−044PRKCDprotein kinase C deltaUpregulated4.09E−045CDK5cyclin dependent kinase 5Upregulated4.77E−046FYNFYN proto-oncogene, Src family tyrosine kinaseDownregulated7.47E−047NR3C1nuclear receptor subfamily 3 group C member 1Downregulated7.89E−048STAT1signal transducer and activator of transcription 1Upregulated7.92E−049FLNAfilamin ADownregulated8.61E−0410IRS1insulin receptor substrate 1Downregulated8.68E−04**Integrated group**1PRKCDprotein kinase C deltaUpregulated5.23E−042CDK5cyclin dependent kinase 5Upregulated6.15E−043PSEN2presenilin 2Upregulated9.13E−044ITGB4integrin subunit beta 4Downregulated0.0010971065DDX3XDEAD-box helicase 3, X-linkedDownregulated0.0012272566DDX58DExD/H-box helicase 58Upregulated0.0012300757MAPK9mitogen-activated protein kinase 9Upregulated0.0021384098FKBP4FK506 binding protein 4Upregulated0.0022410119LMNB1lamin B1Upregulated0.0022828710DSTdystoninDownregulated0.002355127

GO enrichment and KEGG pathway analysis {#Sec15}
---------------------------------------

The output of the DAVID bioinformatics tool provides diverse biological and functional analyses on the prioritized genes in five groups. These include biological processes (BP), cellular components (CC), and molecular functions (MF) for GO analysis as well as the KEGG pathway assessment. Considering stage I, several biological processes (e.g., reactive oxygen species metabolic process, hemopoiesis), cellular components (e.g., proteinaceous extracellular matrix, extracellular exosome), molecular functions (e.g., actin binding, ATP binding), and KEGG pathways (e.g., Influenza A, Tyrosine metabolism) are mainly enriched by DEGs (Fig. [2](#Fig2){ref-type="fig"}a). Moreover, the DEGs at stage II are associated with extracellular matrix organization and cellular response to fibroblast growth factor stimulus in terms of BP, with extracellular exosome and proteinaceous extracellular matrix in terms of CC, with protein binding and actin binding in terms of MF as well as focal adhesion and ECM-receptor interaction in terms of KEGG pathways (Fig. [2](#Fig2){ref-type="fig"}b). The key genes at stage III are enriched in BP related to the positive regulation of the apoptotic process and extracellular matrix organization, in CC related to extracellular exosome and cytosol, in MF related to protein binding and ATP binding, and in KEGG pathways related to Tyrosine metabolism and TNF signaling pathway (Fig. [2](#Fig2){ref-type="fig"}c). Additionally, at stage IV, extracellular matrix organization, extracellular exosome, protein binding, and focal adhesion are the most statistically significant enrichments in BP, CC, MF groups and KEGG pathways (Fig. [2](#Fig2){ref-type="fig"}d). The GO analysis results of the integrated group show that DEGs in groups BP, CC, MF are significantly enriched in complement activation, extracellular exosome, and calcium ion binding. Furthermore, the KEGG pathways analysis for all stages reveals that complement and coagulation cascades and Staphylococcus aureus infection are significantly enriched by prioritized DEGs (Fig. [2](#Fig2){ref-type="fig"}e).Figure 2The biological processes (BP), cellular components (CC), and molecular functions (MF) for GO analysis as well as the KEGG pathway assessment for (**a**) stage I, (**b**) stage II, (**c**) stage III, (**d**) stage IV, and (**e**) Integrated group.

PPI network analysis and hub genes identification {#Sec16}
-------------------------------------------------

Using the Cytoscape and STRING database plugin, PPI networks are constructed for five groups (i.e., stage I (284 nodes and 512 edges), stage II (338 nodes and 1,263 edges), stage III (363 nodes and 1,170 edges), stage IV (346 nodes and 1909 edges), and the integrated group (221 nodes and 519 edges)). Among genes with higher interconnectivity within the constructed PPI networks of five groups, SMC4 (degree = 24, downregulated), FN1 (degree = 50, downregulated), FOS (degree = 42, upregulated), JUN (degree = 69, downregulated), and KIF11 and RACGAP1 (degree = 27, upregulated) for stage I, stage II, stage III, stage IV, and all stages, respectively, have the highest connectivity degrees in their PPI networks.

The significant outcomes for the ClusterOne module analysis in Cytoscape (p-value \< 0.05) reveal 14, 9, 8, 4, and 6 protein modules for stages I, II, III, IV, and the integrated group, respectively.

Verification of central gene biomarkers {#Sec17}
---------------------------------------

### KM plotter tool {#Sec18}

According to the visualization and numerical results obtained from the KM plotter and analysis tool, it has been revealed that 33 out of 53 potential biomarkers have a statistical significant association with the recurrence of free survival for five groups in HER2 breast cancer. Table [2](#Tab2){ref-type="table"} lists the characteristics of each of 53 genes in terms of their stages, gene symbol and expression, and overall p-value.Table 2A summarized list of results of Kaplan--Meier plot tool for 53 potential genes categorized based on their stages and literature screening references.StagesRankGene symbolExpressionOverall P valueRelated cancersReferencesStage I1SMC4Downregulated1.7e−14ER-positive and ER-negative breast cancer^[@CR38]^2IRF7Downregulated0.1861Suppressor of an innate immune pathway in breast cancer^[@CR38],[@CR39]^3POSTNDownregulated0.3289A factor in preventing and treating breast cancer^[@CR38],[@CR40]^4ABATDownregulated8.9e−16ER-positive and ER-negative breast cancer^[@CR41]^5LMOD1Upregulated0.1821Involved in the development of breast cancer^[@CR42]^6TRIM2Upregulated0.7228Invasive and basal-like breast cancer^[@CR43],[@CR44]^7CHRDL1Upregulated2.4e−8Malignant breast cancer^[@CR45]^8MFGE8Upregulated0.1294Triple-negative and ER + breast cancers^[@CR46],[@CR47]^9GLRX5Downregulated0.0001Breast cancerNeurological disorders such as Parkinson's disease and those associated with ageing^[@CR48]^10ELF5Upregulated0.1522TNM staging system for all types of breast cancer and metastasis in breast cancer^[@CR49],[@CR50]^11CSN2Upregulated1.0e−8Invasive breast cancer triple-negative breast cancer^[@CR51],[@CR52]^12PRLRDownregulated7.7e−5Progression of breast carcinoma^[@CR53]--[@CR55]^13PPAP2BUpregulated9.4e−10Coronary artery diseaseBreast cancerTumor growth in breast cancer^[@CR56]--[@CR59]^14FZD2Downregulated3.3e−11Breast cancer^[@CR60]--[@CR62]^15FZD7Upregulated0.6871Breast cancer^[@CR60]--[@CR62]^16GPC4Downregulated0.0004In both MCF-7 (human breast adenocarcinoma) and MCF-10F (normal-like breast cancer)^[@CR63]--[@CR65]^17CERS2Downregulated0.2238Less invasive breast cancer^[@CR66]--[@CR68]^18UGCGDownregulated1.1e−10Triple-negative BCER-negative BC tumorsLung metastases^[@CR69]--[@CR73]^19LIPEUpregulated0.0051Prognostic cofactor in BC Cancer lipolysis^[@CR74]--[@CR76]^20PLIN1Upregulated2.6e−5HER2 tumorsBreast cancerTriple-negative breast cancer^[@CR77]--[@CR79]^Stage II1CCNB2Downregulated \< 1e−16Basal-like, HER2, and luminal breast cancers^[@CR80]--[@CR83]^2OAS3Downregulated0.697Mutated gene in breast cancer^[@CR84]--[@CR86]^3IRF7Downregulated0.1861Suppressor of an innate immune pathway in breast cancer^[@CR38],[@CR39]^4OAS1Downregulated0.5676Development of various cancer types like breast cancer^[@CR85]--[@CR87]^5CDKN1CUpregulated1.9e−5Breast tumors^[@CR88],[@CR89]^6PEG3Upregulated0.0029Several cancers such as breast and ovary cancers^[@CR90],[@CR91]^7PHLDA2Downregulated4.0e−10PRL treatmentTumor progression^[@CR92],[@CR93]^8PLAGL1Upregulated0.3823Breast cancer patients under radiotherapy treatment^[@CR94]^9SGCEUpregulated0.0293Progression of breast cancer invasion in terms of stromal changes^[@CR95]^10SLC22A18Downregulated3.2e−8Breast cancer^[@CR96]^11SERPING1Upregulated1.3e−8Breast carcinoma cells^[@CR97]^12ACTA2Upregulated0.6126Metastasis of breast cancer cells Dimerization of epidermal growth factor receptor (EGFR) and HER2^[@CR98]--[@CR100]^13LCP2Downregulated0.7828Predicting the development of secondary lymphedema followed by breast cancer surgery^[@CR101],[@CR102]^14ABCG1Downregulated0.2418High expression level of ABCG1 transporters in MCF-7 cells^[@CR103],[@CR104]^15ZFP36L1Upregulated0.0507In all types of breast cancer^[@CR105]^16BICC1Upregulated1.0e−10Cystic renal dysplasiaembryonic node, kidney, liver, and pancreas in the mouseBasal-like breast tumors^[@CR106],[@CR107]^17SSPNUpregulated0.0007Several types of cancer, including breast invasive cancer^[@CR108]--[@CR110]^Stage III1FEN1Downregulated \< 1e−16High stages of breast cancerInhibition of the tumor growth^[@CR111]--[@CR113]^2ADH1BUpregulated0.0068Risk factors for breast cancer^[@CR114]--[@CR116]^3IRF7Downregulated0.1861Suppressor of an innate immune pathway in breast cancer^[@CR38],[@CR39]^4ACTA2Upregulated0.6126Metastasis of breast cancer cells Dimerization of epidermal growth factor receptor (EGFR) and HER2^[@CR98]--[@CR100]^5CLDN5Upregulated9.4e−6In both breast tumor stromal (BTS) and prostate tumor stromal (PTS)^[@CR117],[@CR118]^6SLC31A1Downregulated0.4854Progression of breast cancer^[@CR119],[@CR120]^7FBLN1Upregulated3.6e−5In several types of cancer, including breast cancer^[@CR121],[@CR122]^8MFAP4Upregulated5.8e−9In cell adhesion, motility, invasion, and metastasis of BC^[@CR95],[@CR123],[@CR124]^9COL1A2Downregulated0.4121High expression level at higher stages of breast cancer^[@CR125]--[@CR127]^10ASPNDownregulated0.2608Upregulated expression in breast cancer^[@CR128],[@CR129]^Stage IV1NUSAP1Upregulated\< 1e−16A potential biomarker clinically correlated with breast cancer^[@CR130],[@CR131]^2COL6A2Downregulated0.0038Important role in breast cancer development^[@CR132],[@CR133]^3HIST1H2BDUpregulated0.2745ER-positive breast cancerIn breast cancer development^[@CR42],[@CR134]^4HIST1H2BHUpregulated0.0006ER-positive breast cancerIn breast cancer development^[@CR42],[@CR134]^5HIST1H2BKUpregulated8.6e−8ER-positive breast cancerIn breast cancer development^[@CR42],[@CR134]^6HIST2H2BEUpregulated0.1077ER-positive breast cancerIn breast cancer development^[@CR42],[@CR134]^Integrated group1KIF11Upregulated \< 1e−16Triple-negative breast cancer^[@CR135],[@CR136]^2IRF7Upregulated0.1861Suppressor of an innate immune pathway in breast cancer^[@CR38],[@CR39]^3OAS1Downregulated0.5676Development of various cancer types like breast cancer^[@CR85]--[@CR87]^4OAS3Downregulated0.697Mutated gene in breast cancer^[@CR84]--[@CR86]^5SGCEUpregulated0.0293Progression of breast cancer invasion in terms of stromal changes^[@CR95]^6ALDH7A1Downregulated0.0208Breast cancerPotent marker in different types of cancer like prostate cancer^[@CR137]--[@CR139]^7ABCG1Downregulated0.2418Breast cancer^[@CR140]^8C1SDownregulated1.2e−6HER2-positive and basal-like breast cancer^[@CR140]^

### Performance of nine classifiers {#Sec19}

The classification prediction results of all nine non-linear models (i.e., AUC, CA, F1 score, precision, and recall parameters) were investigated. In the *k*-fold cross-validation procedure to keep and possibly increase the stability of the models within the folds, the stratification sampling is used. Except, the performance of the models on the test set, almost all of the machine learning classifiers are trained and cross-validated at the highest values while considering the five-fold cross validation, ten-fold cross validation, stratified shuffle sampling trained on 66% of data, leave one out validation, and trained and tested on the whole dataset. Once the trained model is tested on the test set, the performance results for stages I, II, and III show that naïve Bayes, random forest, and naïve Bayes outperform the other classifiers with 0.87, 0.83, and 0.89 AUC values, respectively. The results are indicative of the fact that the computational classification models are capable of validating the identified genes from the systems biology approach for several stages of breast cancer.

### Literature screening for identified genes {#Sec20}

The other tactic commonly used in the systems biology related studies for validating the identified genes from a specific computational methodology is to gather the required evidence from the literature reports on a specific determined gene in a known disease (i.e., breast cancer). To this end, searching results present that all of the fifty three genes are found to be responsible for cell proliferation, growth, motility, and development at several stages of breast cancer disease. The next section discusses detailed information on these genes (Table [2](#Tab2){ref-type="table"}).

Discussion {#Sec21}
==========

Breast cancer as a heterogeneous disease and the most common invasive cancer is the second leading cause of mortality among women globally^[@CR29]^. During the last thirty years, the trend of mortality rate for breast cancer in developed countries has been dramatically decreased; however, the condition for low-income countries has no significant changes^[@CR30]^. The success in the mortality rate reduction of breast cancer in high-income countries is mostly owing to the improved treatment and early stage diagnosis as well as the appropriate selection and administration of therapies^[@CR30]^. This will be followed by prolonging RFS and OS without complications^[@CR29]^.

In this research, three microarray datasets, including stages I, II, III, IV, and the integrated group, were used, preprocessed, normalized and analyzed from which the significant DEGs for five groups were identified. After that, they were ranked based on the literature involved genes in breast cancer and selected based on the statistical significant p-value \< 0.05. Then, GO and KEGG pathways analyses as well as PPI network construction were performed. The biological processes (BP), cellular components (CC), and molecular functions (MF) were also assessed for enrichment pathways. Moreover, the PPI network analysis using the STRING database revealed several effective hub genes for five groups separately. The significant gene biomarkers with the highest connectivity degree within the hub genes were selected. The validation of the obtained gene biomarkers in terms of recurrence free survival rate in HER2 was statistically carried out by Kaplan--Meier plotter tool with p-values less than 0.05. Moreover, the internal and external validation procedures revealed that the machine learning classification models specifically those developed based on naïve Bayes and random forest by employing various biomarkers at several stages were successful in differentiating between stages and normal samples with good predictive power. Finally, in Table [2](#Tab2){ref-type="table"}, the available evidences collected from the experimental literature reported for breast cancer has been retrieved and listed according to the identified gene biomarkers. Additionally, some of the identified biomarkers were found to be common among different TNM stages. For example, IRF7 was the significant biomarker for stages I, II, and III; and, ACTA2 biomarker was found to have an increasing expression across stages II and III.

According to the outcomes of the current study, we identified a signature of potential biomarkers for BC stages to specifically diagnose breast cancer at developed stages as well as very early stages. These biomarkers could potentially be the target of wet-lab researchers for future investigations. The mathematical models developed for BC prediction and diagnosis at various stages showed significantly high and reasonable performance in clinical outcomes employing the identified biomarkers. It is worth noting that the current study is conducted for the first time that studied the high throughput gene profiling datasets for four stages of BC as well as its integrated stage. Finally, the strong point of the study relied on the three validation methodologies, however, the Kaplan--Meier analysis did not find some of the biomarkers statistically significant.

The systems biology approach could enlighten the path for wet-lab investigators in rapid identification of stages in patients with BC. Moreover, the developed non-linear models could be utilized in prediction procedure after the gene expression values for target biomarkers are determined through experimental tests. The workflow of the current study could be applied for other future microarray studies in terms of involving and investigating the stages of the diseases. Furthermore, the identified biomarkers along with their involved signaling pathways could be beneficial for drug design and discovery agents considering various disease stages and hence, the disease could be controlled, managed and treated at very early stages.

Any researches specifically those carried out on systems biology approaches will have limitations and it seems to be normal. Due to the computational nature of these studies, there will remain gaps between the wet- and dry-labs for further validating the results. The experimental and clinical literature studies do only report on the genes involved in BC disease without stating their stages. The lack of available sufficient microarray datasets in the repository databases investigating the stages of BC made us consider the stages and grades of BC equivalent for the validation process.

During the last decades, extensive genome-wide association studies and next generation sequencing techniques were conducted and applied to identify the potent biomarkers using bioinformatics and experimental approaches for various diseases such as Parkinson's disease and prostate cancer considering the exponential growth of Big Data generation in the field^[@CR31]--[@CR35]^. For future researches, it is useful to investigate the genome-based studies in a centralized manner to provide the datasets in further details in terms of being more specific at the disease stages and the follow-up procedures. Moreover, owing to the large generation of genome datasets, handling and managing them computationally and experimentally are still of many researches' interest in the world. Therefore, close cooperation among systems biologists, bioinformaticians, and biologists is required in to identify potential biomarkers and their involvement in signaling pathways. In other words, understanding the functions of the target signaling pathways in specific diseases is highly important in accelerating the development of new experimental drugs and diagnostics, paving the ways for personalized medicine and improving translational sciences^[@CR32],[@CR36],[@CR37]^.

Conclusions {#Sec22}
===========

In this study, three HER2-negative breast cancer datasets were analyzed to identify differentially expressed genes and construct protein--protein interaction networks as well as GO enrichment and KEGG pathway analyses for the TNM-based staging system. The results indicate that a 53-gene signature is responsible for breast cancer prognosis at various stages. The identified gene signature could be further utilized in personalizing medicine for individuals with breast cancer. The identified PPI modules significantly involved at different stages of breast cancer show a different number of connectivity ranging from 1 to 69. The interesting finding noticeable in the results is that the lower number of interactions within hub genes is not correlated with the importance of genes as potential biomarkers. For example, module 5 with only three genes and two connections shows significant expression (downregulation) in the integrated group. Her2-negative breast cancer was further confirmed by the literature reports. Moreover, the Kaplan--Meier tool for assessing the recurrence-free survival rate is not a measure to exclude a biomarker based only on its statistical significant *p-*value. For instance, in Table [2](#Tab2){ref-type="table"}, there are 20 genes identified to be non-significant in the RFS rate assessment evaluated by the KM tool. However, for example, IRF7 identified as a biomarker for almost all groups has not been significantly related to the RFS rate. However, according to the literature, IRF7 is significantly correlated with breast cancer development. Therefore, non-significant p-value in the KM assessment does not decrease the importance of an identified biomarker. The outcomes of this research have paved the way to evaluate the status of breast cancer development in terms of the TNM-based staging system. All of the identified DEGs were involved in breast cancer as confirmed by the evidence available in the literature derived solely from experimental studies. What is missing from the clinical data in the literature is the staging of the condition, which now can be answered using the panel of gene biomarkers proposed in this study.
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